|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diminished suppression of the P50 auditory evoked potential is a phenotype used in studies of genetic susceptibility in schizophrenia.
|
15625200 |
2005 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gating of the theta-alpha-frequency oscillatory signal in the paired-click paradigm is more strongly associated with schizophrenia and has significantly higher heritability compared with the traditional P50 gating.
|
18762587 |
2008 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PPI and P50 gating measures demonstrate substantially increased heritability in schizophrenia families with a higher genetic vulnerability for illness, providing further support for the commonality of genes underlying both schizophrenia and gating measures.
|
26441157 |
2016 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that P50 auditory evoked potentials can be recorded across multiple sites and reliably demonstrate a physiological abnormality in schizophrenia.
|
20382002 |
2010 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings provide insight into the mechanisms of P50 suppression in schizophrenia and could potentially improve the performance of early identification and diagnosis of schizophrenia for the earliest intervention.
|
31803031 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present findings suggest that COMT Val(108/158)Met polymorphism may not contribute to the risk of schizophrenia and to the P50 deficits, but may contribute to the negative symptoms of schizophrenia among Han Chinese.
|
27315458 |
2016 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The alpha7 nicotinic acetylcholine receptor gene (CHRNA7) is located at 15q13-q14 in a region that is strongly linked to the P50 sensory gating deficit, an endophenotype of schizophrenia and bipolar disorder.
|
18545269 |
2008 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in sensory gating measured by the suppression of P50 auditory event-related potential (ERP) has been implicated in the biological bases of schizophrenia and some other psychiatric disorders and proposed as a candidate endophenotype for genetic studies.
|
17014995 |
2007 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intriguingly, we observed a significant positive association between ADORA2A upregulation and baseline P50 amplitudes in the schizophrenia group.
|
22705363 |
2012 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to the Colorado studies in the non-Colorado studies P50 suppression would not qualify as an endophenotype for schizophrenia.
|
17604606 |
2007 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CHRNA7 gene encoding the α7 nicotinic acetylcholine receptor (nAChR) has repeatedly been linked with schizophrenia and the P50 sensory gating deficit.
|
30974230 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
All four event-related potential indices are potentially valid endophenotypes for schizophrenia, but P50 suppression and P300 amplitude show the closest genetic relationship to schizophrenia.
|
17475740 |
2007 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the P50 sensory gating deficits identified in Chinese patients with schizophrenia may not be involved in the psychopathology of the illness.
|
28606770 |
2017 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results show excess allele sharing for multiple markers in 15q11.2-q25, a chromosomal region previously found linked to a decrease in the normal inhibition of the P50 auditory-evoked response to the second of paired stimuli, a decrease associated with schizophrenia.
|
11803532 |
2001 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associated with alpha 7 nicotinic acetylcholine receptor (α7 nAChR) dysfunction and shown to be improved with nicotine and α7 nAChR agonists, SG has recently been shown to be improved in low P50 suppressing SCZ patients following acute CDP-choline treatment.
|
30920339 |
2019 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we observed no P50 suppression deficit in those EOP patients diagnosed with schizophrenia (N = 39).
|
31649298 |
2020 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A deficit in the inhibition of the P50 evoked response to repeated auditory stimuli has been characterized as a neurobiological deficit in schizophrenia.
|
10813805 |
2000 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A paired-stimulus auditory event- related potential paradigm was used to examine P50 sensory gating in 85 schizophrenia patients (56 medicated with typical antipsychotics and 29 unmedicated), 83 of their first-degree relatives (46 parents and 37 siblings), and 29 normal comparison subjects.
|
12450949 |
2002 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the P50 and N100 decrease correlated with the unaffected subjects' genetic resemblance to schizophrenia patients.
|
16876141 |
2006 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results suggest that the P50 defect is familially associated with schizophrenia.
|
1798824 |
1991 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The defect, a decrease in the normal inhibition of the P50 auditory-evoked response to the second of paired stimuli, is associated with attentional disturbances in schizophrenia.
|
9012828 |
1997 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that, despite the prominent role that P50 abnormalities have played in our understanding of schizophrenia, there is a relative dearth of data examining P50 clinical correlates.
|
16469942 |
2006 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The locus is unusual in that it was first linked to an endophenotype found in schizophrenia, the P50 deficit, and subsequently to schizophrenia.
|
16843094 |
2006 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated two neurophysiological endophenotypes of schizophrenia - P50 sensory gating and mismatch negativity in 22q11.2DS subject and evaluated their association with catechol O-methyltransferase (COMT) and proline dehydrogenase (PRODH) genetic variants.
|
23910792 |
2013 |
|
Schizophrenia
|
0.100 |
Biomarker
|
disease |
BEFREE |
DMXBA is well tolerated in humans and a new study in persons with schizophrenia has found that DMXBA enhances both P50 auditory gating and cognition. alpha7 Nicotinic acetylcholine receptor agonists appear to be viable candidates for the treatment of cognitive disturbances in schizophrenia.
|
17349863 |
2007 |